Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology
A Bayes‐Genis, A Aimo, P Jhund… - European Journal of …, 2022 - Wiley Online Library
The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …
part due to the high costs of conducting large randomized clinical trials that are needed to …
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology
A Bayes-Genis, A Aimo, P Jhund, M Richards… - … JOURNAL OF HEART …, 2022 - iris.sssup.it
: The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …
part due to the high costs of conducting large randomized clinical trials that are needed to …
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology
A Bayes‐Genis, A Aimo, P Jhund… - European Journal of …, 2022 - eprints.gla.ac.uk
The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …
part due to the high costs of conducting large randomized clinical trials that are needed to …
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology
A Bayes-Genis, A Aimo, P Jhund… - … journal of heart …, 2022 - pubmed.ncbi.nlm.nih.gov
The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …
part due to the high costs of conducting large randomized clinical trials that are needed to …
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology
A Bayes‐Genis, A Aimo, P Jhund… - European Journal of …, 2022 - wrap.warwick.ac.uk
The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …
part due to the high costs of conducting large randomized clinical trials that are needed to …
Biomarkers in heart failure clinical trials: A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology
A Bayes-Genis, A Aimo, P Jhund… - European Journal of …, 2022 - research.rug.nl
The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …
part due to the high costs of conducting large randomized clinical trials that are needed to …
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology
A Bayes-Genis, A Aimo, P Jhund, M Richards… - … JOURNAL OF HEART …, 2022 - iris.unibs.it
The approval of new heart failure (HF) therapies has slowed over the past two decades in
part due to the high costs of conducting large randomized clinical trials that are needed to …
part due to the high costs of conducting large randomized clinical trials that are needed to …